I’ve mentioned this before, but don’t exclude off label use of...

I’ve mentioned this before, but don’t exclude off label use of bone marrow derived mesenchymal stem cells in the management of Acute Respiratory Distress Syndrome, an overwhelming recruitment of inflammatory cells to lung tissues, the principal cause of death in the SarsCoV2019 coronavirus pandemic (soon to be called).
There have been numerous studies into their use for this indication including a RCT for safety in 2018

note the wording in this latest announcement “..RYONCIL is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in SR- aGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.”

If our ICUs are overwhelmed by significant numbers of severe ARDS patients, I imagine mesoblast with its advanced approval pathway, could be involved in rapid trials.